[{"orgOrder":0,"company":"SHIRE LLC","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Maribavir","moa":"Phosphotransferase pUL97","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SHIRE LLC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHIRE LLC \/ Shire","highestDevelopmentStatusID":"12","companyTruncated":"SHIRE LLC \/ Shire"}]

Find Clinical Drug Pipeline Developments & Deals by SHIRE PLC

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The results of the SOLSTICE trial are promising and show that maribavir may help with post-transplant CMV viremia, including cases of drug-resistance for which there is an unmet need.

                          Brand Name : SHP620

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 21, 2021

                          Lead Product(s) : Maribavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Takeda Pharmaceutical

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank